Trial Details
COMPLETEDBasic Information
| Clinical ID | c3455 |
|---|---|
| Identifier | NCT02038920 |
| Trial Title | Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Crohn's Disease |
| Interventions | DRUG: Vedolizumab|DRUG: Vedolizumab placebo |
Participant Information
| Sponsor | Takeda |
|---|---|
| City | Aichi-ken |
| Country/Region | Japan |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2014-01-28 |
|---|---|
| Primary Completion Date | 2019-01-25 |
| Completion Date | 2019-05-21 |